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Abstract: Preservation of adult stem cells pools is critical for maintaining tissue 
homeostasis into old age. Exhaustion of adult stem cell pools as a result of deranged 
metabolic signaling, premature senescence as a response to oncogenic insults to the 
somatic genome, and other causes contribute to tissue degeneration with age. Both 
progeria, an extreme example of early-onset aging, and heritable longevity have provided 
avenues to study regulation of the aging program and its impact on adult stem cell 
compartments. In this review, we discuss recent findings concerning the effects of aging on 
stem cells, contributions of stem cells to age-related pathologies, examples of signaling 
pathways at work in these processes, and lessons about cellular aging gleaned from the 
development and refinement of cellular reprogramming technologies. We highlight 
emerging therapeutic approaches to manipulation of key signaling pathways corrupting or 
exhausting adult stem cells, as well as other approaches targeted at maintaining robust stem 
cell pools to extend not only lifespan but healthspan. 
Keywords: aging; stem cells; reprogramming; progeria; longevity; FoxO; Wnt; metabolic 
disease; oxidative stress  
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1. Introduction 
Diseases of aging constitute a huge burden for society, both in terms of economic cost and quality 
life-years of the population. The need for therapies to prevent and/or correct age-related molecular 
events leading to these diseases is growing. These include metabolic syndrome and diabetes, 
atherosclerosis, neurodegenerative diseases, osteoporosis, and cancer (Table 1, [1]). Onset of these 
diseases is highly correlated to advancing age across organ systems. Though molecular mechanisms 
contributing to cancer formation have been extensively studied, the mechanisms underlying age-related 
disease on the whole have only begun to be elucidated [2]. Molecular changes associated with age 
include telomere dysfunction, oxidative stress and deranged mitochondrial metabolism, inflammation, and 
cellular senescence, as well as altered signaling of sirtuins, insulin/insulin-like growth factor-1 (IGF-1), 
and the mammalian target of rapamycin (mTOR) pathway [3–5]. 
Table 1. Conserved aging phenotypes.  
Reprinted by permission from Macmillan Publishers Ltd.: Nature [1], copyright 2008.  
A three-pronged approach exists to combatting diseases of aging in the clinic, and further research 
can improve all three areas. The first arm is prevention of age-related disease through better understanding 
of the molecular causes of systemic aging and age-related disease. The second is pharmacologic 
intervention to reverse, correct, or prevent age-related disease. The third, in lieu of therapies that 
prevent and correct age-related molecular changes, is to surgically repair degenerated tissues. This 
Phenotype H. sapiens M. musculus D. melanogaster C. elegans 
Decreased cardiac function Yes Yes Yes NA 
Apoptosis, senescence (somatic cells) Yes Yes Yes ? 
Cancer, hyperplasia Yes Yes No No 
Genome instability Yes Yes Yes Yes 
Macromolecular aggregates Yes Yes Yes Yes 
Reduced memory and learning Yes Yes Yes NA 
Decline in growth hormone (GH), 
dehydroepiandrosterone (DHEA), 
testosterone, IGF 
Yes Yes ? ? 
Increase in gonadotropins, insulin Yes Yes ? ? 
Decreased thyroid function Yes Yes NA NA 
Decrease in innate immunity Yes Yes Yes Yes 
Increase in inflammation Yes Yes No No 
Skin/Cuticle morphology changes Yes Yes ? Yes 
Decreased mitochondrial function Yes Yes Yes Yes 
Sarcopenia Yes Yes Yes Yes 
Osteoporosis Yes Yes NA NA 
Abnormal sleep/rest patterns Yes Yes Yes ? 
Decrease in vision Yes Yes ? NA 
Demyelination Yes Yes ? No 
Decreased fitness Yes Yes Yes Yes 
Arteriosclerosis Yes No NA NA 
Changes in fat  Yes Yes ? ? 
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includes engineering cells and tissues ex vivo to replace or augment regeneration of those in diseased 
and injured solid organs, nervous system components, and musculoskeletal structures [6–10]. The use 
of adult stem cells for this third approach, as well as the suspected regenerative functions of adult stem 
cells in vivo, has led researchers to closely consider the effects of systemic aging on the stem cell pools 
of an individual.  
Stem or progenitor cells are generally considered highly promising candidate cells for regenerative 
applications not only because they possess a high proliferative capacity and the potential to differentiate 
into other cell types [11–14], but also because they can be sourced autologously, eliminating any concerns 
about rejection or need for immunosuppressive therapy [8,15–19]. They possess innate immunomodulatory 
properties, home to sites of injury or inflammation, and direct the cells around them to begin a repair 
process via the production of bioactive factors and signaling molecules. Stromal stem cells are 
currently in clinical use as gene delivery agents to enhance tissue regeneration, to destroy cancer cells, 
and to regenerate cartilage and bone, and hematopoietic stem cells (HSCs) have been in clinical use for 
many years to reconstitute the immune system in cancer and other illnesses. However, studies of adult 
stem cells show that they do not fully retain their proliferative and multi-lineage differentiative 
capabilities in aging humans or after prolonged ex vivo propagation. Genetically or epigenetically 
modifying adult stem cells either to rejuvenate those of an elderly individual or to confer resistance to 
cellular aging during ex vivo propagation would yield a favorable cell source for regenerative medicine 
applications. Understanding the events that contribute to stem cell aging and developing methods to 
reverse those changes will also facilitate development of therapies to maintain in vivo adult stem cell 
pools as people age. 
2. Adults Stem Cells and Causes of Aging  
Adult stem cells are thought to reside in vivo as self-renewing pools and facilitate repair/replacement 
of damaged tissues over the lifespan of the organism. Stem cell quiescence lies on one end of a 
spectrum of self-renewal potential spanning from quiescence, to robust proliferation, to senescence, 
and death. Maintaining stem cell quiescence is essential for preserving the long-term self-renewal potential 
of the stem cell pool in a number of organ systems, such as the brain, bone marrow, musculoskeletal 
system, and skin [20,21]. There is an emerging body of evidence that altered and decreased function of 
adult stem cells in vivo secondary to accumulated metabolic stress plays an important role in the 
initiation of diseases of aging [22,23]. This is true in multiple organ systems. For example, in bone 
studies on the osteoblastic versus osteoclastic differentiation of progenitors in aging mouse models 
have shown that, over time, osteoblastic potential of stromal progenitors decreases, while osteoclastic 
differentiation of hematopoietic progenitors increases. This suggests an organismal aging program that 
results in common diseases of aging, including decreased bone quality [24]. Another example is in the 
immune system, where clonal diseases of myeloid stem cells occur more frequently and become more 
resistant to therapy with increasing age [25]. The hypothesis is now being investigated that this is 
caused by age-related genomic instability, causing a defective DNA damage response that results in 
abnormal differentiation of HSCs (reviewed in [26]).  
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2.1. Self-Renewal and Maintenance of Stem Cell Pools 
It would appear that the primary hit to adult stem cells during aging is to their  
proliferative/self-renewal potential more than their ability to undergo terminal differentiation 
effectively, although this is somewhat lineage-dependent. HSC populations in mice have been shown 
to actually increase in number and frequency with age, but with reduced ability to divide, delayed cell 
cycle progression, and age-related genetic changes in cell cycle regulators such as p21 and p18 [27]. In 
humans lower numbers of neuronal progenitor cells have been found in aged brains compared to young 
brains, but this population is still responsive and proliferates in response to ischemic injury [28]. 
Circulating hematopoietic progenitors were shown to increase more dramatically in younger patients 
after cardiopulmonary bypass graft than in older patients, and advanced age was associated with 
impaired coronary microvascular response to vascular endothelial growth factor (VEGF) [29]. 
Conversely, advanced age has been associated with a higher S-phase fraction of circulating HSCs in 
patients with aplastic anemia, but this predisposed them to dysplasia and conversion to acute myeloid 
leukemia, indicative of abnormal HSC function [30]. Studies of adult stem cell isolation yield in 
elderly individuals have shown that equivalent numbers of adipose-derived mesenchymal stem cells 
(MSCs) can be isolated from older individuals undergoing vascular surgical procedures as from young, 
healthy individuals [31,32].  
The question remains whether those cells can be adequately expanded in tissue culture and whether 
they are able to mobilize, proliferate, and effect tissue repair in vivo when they are needed. In fact 
these same studies [31,32] have shown that while advanced age does not impact availability of stem 
cells, fat from patients with diabetes yielded significantly fewer stem cells than fat from non-diabetic 
patients. This would suggest that stem cells in the context of aging should probably be considered 
distinctly from stem cells in the context of diseases of aging. Advanced glycation endproducts, which 
accumulate in the setting of advanced age or diabetes, have been shown to directly impair HSC 
function and induce MSC apoptosis [33,34]. 
Other studies have shown that patients of increasing age yield adipose-derived MSCs that can be 
differentiated. However, frequently these studies do not compare the quality of differentiation to that 
achieved with cells from younger patients, leaving the question of whether differentiation potential has 
declined unanswered [35]. In one study looking at the efficacy of MSC transplantation following 
myocardial infarction, cells from aged donors did not perform as well as cells from younger donors [36]. 
Similarly, MSCs obtained from young individuals have been induced to undergo neuroectodermal 
differentiation in vitro, but this effect cannot be replicated in MSCs from elderly individuals [37].  
A study demonstrating that lineage fate of MSCs from human donors was unaffected by donor age also 
found that activation from quiescence, including replicative function and quality of differentiation, was 
negatively impacted by advanced donor age [38].  
2.2. An Aging Immune Milieu 
A further complication in teasing apart the effects of aging on adult stem cell compartments is the 
changing interaction between stem cell types and with an aging immune system (reviewed in [39]). For 
example, the health and age of marrow-derived stromal stem cells has been shown to have an impact 
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on the quality of HSCs, both in vivo and upon co-culture ex vivo [40,41]. Chronic pro-inflammatory 
cues, such as circulating inflammatory cytokines, which are upregulated in aged individuals [42], may 
both dysregulate the differentiation of stromal cells, and in turn negatively impact their ability to 
support hematopoietic progenitors, resulting in further dysregulation of the immune compartment. 
Mouse models of premature aging have demonstrated induction of NF-κB signaling and secretion of 
high levels of pro-inflammatory cytokines as a causative factor in the accelerated aging phenotype [43]. 
2.3. Genomic and Transcriptomic Data 
Network analyses of signaling pathways differentially regulated in aging suggest that, rather than 
being a tightly regulated, well-defined program, aging may reflect a destabilization of other programs 
over time. On the other hand, extreme differences in lifespan between evolutionarily closely related 
species would argue that there is a dominant central aging program that determines organismal 
lifespan. Research indicating that survival to old age is not correlated with absence of risk alleles for 
common age-related diseases, such as cancer, coronary artery disease, and type 2 diabetes also supports 
the idea of a prevailing aging program [44].  
Similarly, gene expression profiling has been done in adult stem cells to examine the effects of  
age in the setting of osteoarthritis and vice versa, revealing that different sets of genes were 
differentially regulated in association with either aging or osteoarthritis [45,46]. The pathways 
associated with aging were closely associated with glycan metabolism, in contrast to osteoarthritis, which 
was heavily associated with aberrations in immune signaling genes and regulators of self-renewal and 
differentiation, such as Wnt-related transcripts. Another gene expression profiling study looking 
specifically in human skin showed sex-specific age-related changes, with females displaying increased 
expression of pro-inflammatory genes that was not observed in males [47]. A recent meta-analysis of 
genome-wide association studies performed to identify polymorphisms associated with diseases of 
aging revealed that genes associated with multiple diseases known to occur in elderly individuals are 
generally associated with pathways regulating either inflammation or cell senescence, with the most 
highly significant susceptibility locations mapping to regulators of senescence, leading the authors to 
conclude that germline genetic heterogeneity in regulators of these pathways contributes significantly 
to onset of age-related disease [3]. 
2.4. Heritable Longevity 
Some of the most pertinent research to understanding the molecular mechanisms underlying aging, 
rather than the molecular effects resulting from aging, is in the area of heritable longevity and premature 
aging in humans. Many genetic variants, the value of which is unknown, have been identified in areas 
associated with longevity and disease resistance, including dietary restriction, metabolism, autophagy, 
stem cell activation, tumor suppression, DNA methylation, progeroid diseases, stress response, and 
neural processes [44,48]. One of these variants, a single nucleotide polymorphism (SNP) in the gene 
TOMM40, was found not to be directly linked to decreased longevity, but instead reflects a linkage 
disequilibrium with multiple isoforms of the APOE gene that are deleterious to longevity and have 
been strongly associated with elevated cholesterol, cardiovascular disease, Alzheimer’s disease, and 
cognitive decline and dementia, as well as serum IGF-1 levels in women [49].  
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Several genetic variants in the insulin/IGF-1 pathway have been associated with longevity or 
increased healthspan and include multiple SNPs from nine different genes along this signaling axis: 
AKT1, FOXO1A, FOXO3A, GHR, GHRHR, IGF1R, IGFBP3, IGFBP4, and PTEN. Indeed, common 
SNPs in AKT1 and FOXO3A have consistently been associated with longevity in three independent 
cohorts [50], as well as a SNP in the CAMKIV gene, which in vitro has been shown to activate AKT, 
SIRT1, and FOXO3A [44]. A SNP in the MNPP1 gene, which codes for an enzyme similar to 
phosphatase and tensin homolog (PTEN) that regulates intracellular levels of polyphosphates, critical 
for determining the rate of cell proliferation, has also been associated with longevity in meta-analyses 
of large-scale genome-wide association studies. 
2.5. Premature Aging 
Progeria, or premature aging, reflects an opposite outcome from long lifespan or long healthspan. 
Individuals with Hutchinson-Gilford progeria syndrome (HGPS), caused by a point mutation in 
LMNA, the gene for the lamin A nuclear envelope protein, experience premature aging as a result of 
nuclear defects that lead to impaired cell division and transcriptional deregulation (reviewed in [51]). 
This point mutation activates a cryptic splice donor site, leading to production of a dominant negative 
form of the lamin A protein which has been named progerin; this splice variant is also expressed at low 
levels in normal individuals, accumulates in some cell types with normal aging, and is expressed at 
higher levels in several human cancer cell lines [52]. Similarly, individuals with Werner’s syndrome, 
who display adult-onset progeria, have a defect in the WRNp protein, which is critical for DNA 
replication and repair.  
In both aging syndromes, telomere shortening and DNA damage synergistically destabilize the 
genome, leading to accelerated p53-dependent senescence and apoptosis; this phenotype has been 
rescued in experimental models by over-expression of hTERT or p53 inactivation [53–55], and this 
process has also been documented in normal human fibroblasts [56]. Increased rates of nuclear DNA 
damage in all cell types, in combination with impaired stem cell regeneration of damaged tissues, are 
thought to be directly responsible for the accelerated aging phenotype that is observed. As a result  
this disease has inspired the generation of several aging models, both transgenic animal models and  
in vitro systems employing induced pluripotent stem (iPS) cells derived from fibroblasts of HGPS 
patients [57–64]. From these models, it has been learned that high rates of cellular senescence and 
apoptosis due to increased nuclear DNA damage correlate very well with decreased lifespan, independent 
of increased rates of cancer, whereas models with comparatively low rates of cellular senescence and 
apoptosis display increased lifespan [55,65].  
Comparison of tissue phenotypes observed in normal aging and HGPS suggests that lamin A may 
play an important role in sensing and transducing stress response signals critical for adult stem cell and 
niche maintenance in all individuals [66]. Progerin has been demonstrated to accumulate in MSCs, 
vascular smooth muscle cells, and fibroblasts, both in in vitro disease models and in human subjects, in 
association with disease and other signs of aging in the skin, musculoskeletal, and cardiovascular 
systems [59,67,68]. MSCs have been shown not only to be most susceptible to progerin accumulation 
and failed cell division, but also more susceptible to oxidative and other kinds of stress in the context 
of progerin accumulation both in vitro and in vivo. In the absence of normal lamin A or abundance of 
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progerin, mild oxidative stress is sufficient to induce nuclear disorganization and premature 
senescence, confirming the importance of this protein for maintaining tolerance to reactive oxygen 
species [69]. These factors combine to effectively wipe out this adult stem cell pool in HPGS patients, 
leaving them with a critical deficit in tissue regeneration [59,70], and it is likely this same process 
plays a role in progressively declining MSC function with normal aging.  
2.6. Ex Vivo Stem Cell Aging 
A wholly separate but potentially instructive area of research involves those studies focused on  
ex vivo aging of adult stem cells. Ex vivo stem cell aging has been shown to be very similar to in vivo 
stem cell aging in rodent models, but this has not held true on a molecular level in every study done 
with human cells. For example, telomere shortening, which drives cellular senescence in cultured 
human cells, is not observed in rodent cells clearly undergoing replicative senescence [71]. Despite 
this finding, there does appear to be an association between ex vivo cell senescence and organismal 
lifespan, and studies of telomerase mutations in humans have revealed an association with diseases of 
aging in which tissue compartments require a high degree of cell self-renewal [72]. Similarly, short 
telomeres have been linked with some tissue-specific degenerative diseases, and telomere length is 
evaluated as a clinical parameter in determining therapeutic approaches (reviewed in [73]). Ablation of 
senescent cells in progeroid mice has been shown to delay or rescue the aging phenotype at the 
organismal level, implicating senescent cells in the pathogenesis of age-related disease in vivo [74]. 
Taken together, these findings suggest that the study of ex vivo senescence could yield information 
pertinent to in vivo aging.  
Examination of adult stem cell proliferation in ex vivo tissue culture have shown that MSC 
proliferation declines precipitously after repeated passaging [75]. Studies of differential gene 
expression between early and late passage MSCs showed progressive down-regulation of genes 
associated with self-renewal, such as OCT4, SOX2, and TERT and up-regulation of genes associated 
with osteogenic potential; this was accompanied by an increased propensity for spontaneous 
osteogenic differentiation and decreased proliferation over time [76]. The authors of this work noted a 
concomitant increase of epigenetic dysregulation of histone H3 acetylation in association with these 
differentially regulated genes, and correction of this dysregulation with fibroblast growth factor  
(FGF) administration during culture, resulting in promotion of proliferation and suppression of  
spontaneous osteogenesis. 
3. Metabolic Stress and Adult Stem Cell Aging  
Adult stem cells experience many stressful insults in the course of a lifetime of tissue repair. 
Regulation of energy metabolism is critical to withstanding stress, which comes in the form of nutrient 
deprivation, oxidative stress, DNA damage, pathogens, and other stressors. Studies on the molecular 
causes/effects of aging in adult stem cells have shown that in aged subjects these cells display an 
altered proteome, with proteins involved in cytoskeletal organization and anti-oxidant defense being 
age-dependent and associated with functional impairment of the cell, including decreased responsiveness 
to physical environmental cues and decreased resistance to oxidative stress [77].  
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3.1. Oxidative Stress 
Mesenchymal stem cells (MSCs) from both bone marrow and adipose tissue have been shown to 
have reduced capacity for oxidative stress with increasing donor age [78–80]. Studies in patients 
undergoing percutaneous coronary intervention after myocardical infarction have shown that self-renewal 
capacity and therapeutic efficacy of autologous bone marrow-derived MSCs can be correlated with 
blood gas levels in the marrow niche. This indicates that the function of these cells is highly dependent 
on their redox status [81].  
Oxidative stress is increasingly being recognized as a fundamental underlying component of the 
aging process, leading to hyperactivity of pro-growth pathways like insulin/IGF-1 and mTOR, subsequent 
accumulation of toxic aggregates and cellular debris, and ultimately activation of cell death/survival 
pathways leading to apoptosis, necrosis, or autophagy (reviewed in [82]). Insulin/IGF-1, mTOR, 
FoxO, AMP-activated protein kinase (AMPK), and the sirtuin pathways all play a role in stem cell 
maintenance and differentiation through their sensing and regulation of energy availability in times of 
stress (reviewed in [83–85]), and these same pathways have been associated with advancing age in 
humans (Figure 1, [86]). Studies of two independent cohorts testing the expression of mTOR-related 
transcripts in aging found robust associations for genes involved in insulin signaling (PTEN, PI3K, 
PDK1), ribosomal biogenesis (S6K), lipid metabolism (SREBF1), cellular apoptosis (SGK1), 
angiogenesis (VEGFB), insulin production and sensitivity (FOXO), cellular stress response (HIF1A) 
and cytoskeletal remodeling (PKC), all of which were negatively correlated with advancing age, and 
for genes involved in inhibition of ribosomal components (4EBP1) and inflammatory mediators 
(STAT3), which were positively correlated with advancing age [87]. 
Figure 1. Environmental cues and evolutionarily conserved pathways that regulate the 
aging process in diverse eukaryotic phyla. Reprinted by permission from Macmillan 
Publishers Ltd.: Cell Death and Differentiation [86], copyright 2008. 
 
  
J. Clin. Med. 2014, 3 96 
 
 
3.2. Stress Response and Homeostasis  
In response to sublethal stress-induced insults, cells must remove or repair damaged components in 
order to reestablish homeostasis. Autophagy is one of the processes by which cells accomplish  
stress-induced metabolic adaption, and it has been identified as a critical mechanism for maintenance 
of stem cell function with aging [88]. Basal levels of autophagy are higher in adult stem cells from 
many tissue types compared to terminally differentiated cells, and autophagy is down-regulated during 
differentiation of adult stem cells. mTORC1, AMPK, and the sirtuins have all been shown to 
differentially regulate autophagy in response to nutrient stress, suggesting one possible connection 
between starvation and resistance to aging (reviewed in [89]).  
The sirtuins are a family of nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases 
which are critical for maintaining cellular homeostasis in the face of age-related metabolic and other 
stressors, helping to prevent diseases of aging, but they are not thought to be involved in regulation of 
organismal lifespan (reviewed in [90]). Sirt1 coordinates stress responses and cell metabolism and 
regulates replicative senescence, is found in much higher levels in stem cells than differentiated cells, 
and is down-regulated upon differentiation of stem cells [91]. HSCs are dependent upon Sirt1 for 
maintenance of their undifferentiated state through elimination of reactive oxygen species, FoxO 
activation, and p53 inhibition [92]. In the case of embryonic development or tissue revascularization 
following ischemic injury, Sirt1 promotes endothelial progenitor branching and proliferation, although it 
is not required for endothelial cell differentiation [84]. These effects of Sirt1 are a result of its negative 
regulation of downstream effectors such as FoxO and Notch proteins. Resveratrol, a known Sirt1 
agonist, has been shown to enhance osteogenic differentiation over adipogenic differentiation of MSCs, 
thereby conferring bone-protective effects and highlighting the importance of Sirt1 and its downstream 
target FoxO3 in preventing age-related osteoporosis [93]. Sirt1 confers sensitivity to insulin when 
over-expressed, and has been shown to be significantly down-regulated in cells resistant to  
insulin [94]. Given the critical function of this enzyme for maintaining robust adult stem cell pools and 
regulating their differentiation in multiple organ systems, its down-regulation in the context of insulin 
resistance provides one clue as to why metabolic disease is so damaging for regenerative processes in 
aging individuals. 
4. Adult Stem Cells: Caught in the Balance between Cancer and Metabolic Disease 
Regulation of organismal longevity is coordinated through many intersecting signaling pathways 
that maintain a tight balance between carcinogenesis and apoptosis in individual cells [95,96]. For a 
stem cell, which over the course of its existence travels on the self-renewal spectrum from unlimited 
proliferative potential to senescence and ultimately death, many of these pathways are at work in 
opposition to each other all the time (Figure 2, [97]). A number of the well characterized pathways that 
control cell proliferation in cancer are now being examined for their role in regulating stem cell 
renewal and aging. One group took advantage of this similarity in regulatory networks between cancer 
cells and stem cells to study the effect of anti-aging reagents on induction and maintenance of  
self-renewal behavior and underlying mechanisms in stable cancer cell lines. They found that BMI1, a 
well-known proto-oncogene and critical regulator of self-renewal in multiple adult stem cells 
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populations, took over the epigenetic program in cells retrogressing to a more primitive state as a result 
of the anti-aging treatments [98]. This proto-oncogene has also been identified as a critical promoter of 
osteogenesis through its coordinated stimulation of SIRT1 expression and inhibition of p16, p19, and 
p27 in response to pararthyroid hormone related peptide (PTHrP) signaling [99], resulting in enhanced 
proliferation, decreased apoptosis, and decreased adipogenic differentiation of MSCs [100].  
Figure 2. (a) PTEN is active in quiescent long term-HSCs and represses protein kinase B 
(PKB) signaling towards downstream components (such as mTOR and FoxO). Active 
FoxO programs cells to remain quiescent by cell-cycle repression and other mechanisms, 
but also allows survival by switching to a metabolic program of gluconeogenesis and fatty 
acid metabolism, together with elimination of reactive oxygen species (ROS). Ataxia 
telangiectasia mutated (ATM) may function in conjunction with FoxO through an as yet 
undefined mechanism, probably involving regulation of ATM expression by FoxO. Proteins 
active in LT-HSCs are shown in white elipses; (b) HSCs are driven to proliferate after loss 
of PTEN or FoxO. PKB and other downstream phosphoinositide 3-kinase (PI(3)K) events 
are active in this situation (indicated in white elipses). Loss of FoxO results in increased 
intracellular ROS levels, which in turn activates p38. If PI(3)K signaling is required to drive 
LT-HSCs into proliferation under normal conditions, what external niche signals would do 
so are unknown. However, PI(3)K signaling may function in cooperation with other 
signaling pathways, and this is illustrated by c-Myc—a downstream target of Wnt 
signaling. Myc represses FoxO, and may also independently regulate control of 
proliferation; (c) Differentiation of lineage-restricted cells further continues and is guided 
by extracellular signals such as interleukins (ILs) and various colony stimulating factor 
(CSFs); (d) After executing their function, all hematopoietic cells die and regeneration 
begins. Modified with permission from Macmillan Publishers Ltd.: Nature Cell  
Biology [97], copyright 2007. 
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4.1. Proliferation vs. Oncogenic Resistance at the Cellular Level 
Ultimately aging at the cellular level is suspected to result from a disruption of the balance between 
alternative cellular states (reviewed in [101]), with proto-oncogenes that promote stem cell function, 
such as BMI1 and Wnt/β-catenin, operating in opposition to tumor suppressor genes that induce death 
or senescence in stem cells, such as INK4A (p16Ink4a) and ARF (p19Arf) [102]. In the hematopoietic 
system, aging has been closely linked with impaired repair response to DNA damage, leading to 
increased propensity for dysplastic syndromes and ultimately cancer [26]. The occurrence of cellular 
senescence, in contrast to quiescence or proliferation, is thought to be a protective response against 
oncogenic insults. Expression of INK4A has been shown to increase with age, and this progressive 
increase in tumor suppressor activity independent of levels of proto-oncogene expression may account 
for reduced stem cell activity with aging [102]. The tumor suppressor AIMP3/p18, endogenous levels 
of which increase in aged human tissues, drives cells to senescence when overexpressed. In transgenic 
mice p18 promotes a progeroid phenotype through selective degradation of normal lamin A [103].  
A frequently raised concern about the therapeutic use of autologous adult stem cells from aged 
individuals is precisely that with the life-long accumulation of potentially mutagenic insults to their 
DNA, if they are still capable of robust self-renewal, they might pose an increased risk for cancer upon 
mobilization or exogenous activation [104]. That said, several studies have indicated that over the 
course of human development, as the need for growth decreases and the risk of oncogenesis increases, 
requirements for critical tumor suppressor mechanisms change, with adult stem cells displaying 
dependence on self-renewal regulatory signaling pathways that are not necessary in embryonic or even 
fetal stem cells [105]. 
4.2. Growth versus Oncogenic Resistance at the Organismal Level 
Just like the constant struggle between carcinogenesis and apoptosis at the cellular level, growth 
versus somatic preservation is also balanced at the organismal level throughout life. One emerging 
hypothesis of aging is that it reflects tissue dysfunction due to hypertrophy and hyperplasia, rather than 
tissue damage [106], plus senescence resulting from prolonged hypertrophic arrest [107]. Insulin/IGF-1 
signaling, turned on at the systemic level in response to glucose or growth hormone, is a potent 
stimulator of cell growth and proliferation via the Akt-TOR pathway, regulating organismal growth in 
childhood and anabolic metabolism in adulthood. As discussed above, gene variants along this 
pathway have been associated with longevity (age ≥92 years) in clinical cohorts [50]. Interestingly, 
reduced IGF-1 levels are present not only in extremely long-lived individuals, but also in progeroid 
individuals. This illustrates that suppression of this axis is not a causative factor in increasing or 
decreasing lifespan and healthspan, but rather an adaptive response against accumulating DNA damage 
at the expense of growth and other metabolically expensive processes [108–110]. Adult stem cells are 
highly responsive to insulin/IGF-1 signaling and programmed to replicate and repair; both metabolically 
costly activities. As somatic DNA is exposed to a lifetime of potentially mutagenic hits, these 
metabolically active cells are increasingly caught in the balance between cancer and metabolic disease, 
the hallmark of which is insulin resistance.  
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4.3. Manipulation of Growth Pathways 
Pharmacologic agents targeting the insulin/IGF-1 axis—both neutralizing monoclonal antibodies 
against IGF-1/IGF-1R and tyrosine kinase inhibitors which target the insulin receptor and IGF-1R—have 
been developed to treat cancer, but in clinical trials to evaluate these agents, a common side effect was 
hyperglycemia due to inhibition of insulin signaling [111]. Similarly, metformin, an agent already  
in use for the treatment of type 2 diabetes, has been shown to reduce the incidence of cancer,  
in part through AMPK-dependent inhibition of mTOR (thus cell growth) and AMPK-independent cell 
cycle arrest [112], but also in part through decreased levels of insulin and insulin resistance  
(reviewed in [113–115]).  
Manipulating this pathway to combat disease in aging humans is fraught with complications, and 
creative, highly specific approaches are required to avoid trading one disease for another. This is 
especially important to consider in the case of stem cells. Chemotherapy-resistant cancer stem cells, 
characterized by a high degree of metabolic flexibility, have been shown to be very sensitive to 
metformin [116,117]. One of the proposed mechanisms of action of metformin on cancer stem cells is 
interference with TGFβ-induced epithelial-to-mesenchymal transition [118], and metformin has been 
shown to prevent transcriptional activation of OCT4 through AMPK activation [119]. These properties 
of metformin should generate concern about the effects on adult stem cell populations during its use 
for treatment of diabetes and cancer, but studies have also shown that while metformin-induced AMPK 
activation interferes with mechanisms critical for cancer stem-cell related tumorigenesis, adult stem 
cells may be less susceptible to disruption by metformin [120].  
Accumulating evidence suggests that pathways governing self-renewal have distinct effects on 
normal stem cells and cancer stem cells even within the same tissue. In their study demonstrating adult 
stem cell dependence on PTEN in the hematopoietic compartment, in contrast to cancer stem cells, 
Yilmaz et al. [121] discussed several mechanisms through which maintenance of normal adult stem 
cells may be different from that of cancer stem cells. They suggested that persistent activation of 
PI(3)K in the absence of PTEN inhibition may lead to the accelerated exit of normal HSCs from the 
progenitor pool [121], and later showed that PTEN deficiency induces senescence and apoptosis in 
normal HSCs via increased expression of the cell cycle-regulating tumor suppressors p16 and  
p53 [122], in contrast to other cells from the hematopoietic compartment. Effects of PTEN deficiency 
on the HSC pool could be rescued by rapamycin, indicating events downstream of mTOR are 
responsible, for example changes in Akt signaling. It is known that mTOR inhibition activates FoxO 
signaling, resulting in increased stress resistance and longevity in invertebrate models [123]. It was 
hypothesized that prolonged rapamycin treatment might actually be inhibiting Akt signaling through 
mTORC2 rather than activating Akt through mTORC1, leading to loss of FoxO function, an attractive 
explanation for the accelerated stem cell aging observed with PTEN deficiency [124]. However, thus 
far this has not been shown to be the case in PTEN-deficient HSCs [105,122]. Cancer stem cells are 
able to escape this process through secondary mutations that attenuate mTOR-dependent tumor 
suppressive mechanisms [122].  
Similar results have been obtained in HSCs with deletion of the cell cycle regulator p21, showing 
that control of cell cycle entry under conditions of stress is crucial for maintenance of stem cell 
quiescence and prevention of premature deletion of an entire adult stem cell pool [125]. Indeed, even 
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in the case of pluripotent cells, metformin appears to have split effects: When administered to mice 
after iPS cell transplantation, metformin prevented teratoma formation but did not interfere with tissue 
formation from all three germ layers [126]. The findings are controversial regarding the effect of 
metformin on the differentiation of adult stem cells. In one study on rat marrow-derived MSCs, 
metformin enhanced osteogenesis at the expense of adipogenesis, presumably through modulation of 
peroxisome proliferator-activated receptor (PPAR)γ activity [127], opposite of the effect observed with 
glitazones, which activate PPARγ and can lead to bone loss [128]. However in another study of human 
and rabbit MSCs, metformin did not induce osteogenesis, while 5-aminoimidazole-4-carboxyamide 
ribonucleoside (AICAR), a small molecule activator of AMPK, induced robust osteogenic 
differentiation even in the absence of induction medium [129]. In studies of primary osteoblasts, 
activation of AMPK signaling was observed during early differentiation events, but chemical induction 
of AMPK with metformin blocked terminal differentiation and matrix mineralization [130].  
4.4. Metabolic Dysregulation 
Even in the absence of pharmacologic intervention targeting these pathways, metabolic disease is 
frequently the trade-off associated with oncogenic resistance. Perturbation of the aforementioned 
lifespan determinant pathways, such as SIRT1, insulin/IGF-1, FoxO and mTOR, leads to the 
development of metabolic syndrome features in mice [131]. Metabolic syndrome—characterized by 
the triumvirate of high cholesterol, high blood pressure, and high fasting blood glucose—and type 2 
diabetes in turn lead to accelerated aging. In the case of full-blown type 2 diabetes, this accelerated 
aging is evidenced at the cellular level by slower DNA unwinding, increased collagen cross-linking, 
capillary basement membrane thickening, increased oxidative damage, and decreased Na+K+-ATPase 
activity, and at the organismal level by an increased incidence of cataracts, vascular disease and 
associated events (myocardial infarction, stroke, and pressure ulcers), cognitive decline, hip fracture, 
pain, incontinence, infections, and depression [132]. 
A vicious cycle then evolves whereupon metabolic disease can in turn indirectly increase oxidative 
stress and associated dysregulation of adult stem cell function [133]. An expanded adipose compartment 
produces higher levels of free radicals, leading to oxidative stress, one of the effects of which is to 
disrupt adipocytokine production. Adiponectin, an adipocytokine down-regulated in obesity and 
metabolic syndrome, is an important regulator of glucose and fatty acid metabolism, and in combination 
with other adipose-derived hormones, such as leptin, prevents insulin resistance (reviewed in [134]). 
One of the critical functions of adiponectin is to oppose the actions of angiotensin II, local (adipose) 
over-production of which also contributes to a pro-inflammatory state and increases oxidative stress  
in vivo (reviewed in [135]).  
The resultant disruption to homeostasis has many downstream effects that further increase inflammation 
and co-opt adult stem cells in worsening the situation. First, trafficking of multiple types of adult stem 
cells is likely altered in response to the inflammatory adipocytokines (IFNα, TNFα, IL-6) up-regulated 
during this process, leading some to speculate about adult stem cell exhaustion and the resulting 
impairment of tissue repair as the primary mechanism underlying long-term effects of metabolic 
disease, and in a less fulminant way the aging process in general [23]. Additionally, fate of adult stem 
cells is differentially regulated in this environment. For example, enhanced production in metabolic 
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syndrome of 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) by the cytochrome P450 system 
and its cyclooxygenase-2-derived product 20-OH-PGE2 act to bias MSCs toward adipogenic differentiation 
through up-regulation of PPARγ and β-catenin, resulting in compounded inflammation-driven 
adipogenesis and impaired peripheral tissue maintenance through loss of otherwise uncommitted 
progenitors in patients with these disorders [136–138]. Activation of PPARγ has been shown to impair 
IGF-1 signaling in the marrow microenvironment [138], further contributing to skeletal loss, disruption 
of metabolic homeostasis, and potentially altering organismal lifespan [139]. In this way adult stem 
cells contribute to the pathogenesis of metabolic disease and also are impaired in their physiologic 
function by the presence of metabolic disease. 
Despite the occurrence of insulin resistance and other attempts by cells to thwart oncogenic 
transformation in an aging metabolic system, metabolic disease is frequently associated with a higher 
incidence of cancers [140], particularly in sites with a high degree of cell metabolism and/or turnover. 
In part this reflects not a causal relationship but twin manifestations of a stressed system struggling and 
failing to restore homeostasis. However, the peripheral insulin resistance of metabolic disease also 
drives cancer growth through a decrease in hormone binding globulins (thus higher free steroid 
hormone levels), dysregulation of inflammatory cytokine and steroid and peptide hormone levels, and 
most importantly compensatory hyperinsulinemia, with many cancer cell types expressing high levels 
of insulin receptors and IGF receptors [141]. Large chromosomal clonal mosaic events, the incidence 
of which has been shown to increase with age [142], have been associated both with type 2 diabetes 
and with an increased risk of blood and solid organ cancers [143,144]. Clonal mosaicism in the blood 
compartment in particular further contributes to cancer formation, as well as increased susceptibility to 
disease in general, by leading to a reduced number of immune cell clones in circulation and resultant 
immunosenescence with age [142]. 
5. Illustrations of Deranged Signaling in Aging  
5.1. Canonical Wnt Signaling: A Critical Pathway in Aging Stem Cells 
As the MSC pool is skewed away from an osteogenic fate toward an adipogenic one in  
metabolic disease, there is massive disruption of signaling pathways that have implications for adult 
stem cells beyond differentiation. One of these pathways is the Wnt pathway, which is not only critical 
during development for axial patterning, but is also critical in stem cell fate determination. Many 
developmental events in stem cells are regulated by Wnt signaling, including self-renewal, 
differentiation, aging [145,146], and senescence [147–149]. Extensive crosstalk has been documented 
between Wnt signaling and FGF, prostaglandin E2 (PGE2), bone morphogenetic protein (BMP),  
Notch [150,151], TGF-β, and SMAD signaling pathways, with the common downstream target of this 
crosstalk being β-catenin [152,153]. In canonical Wnt signaling, β-catenin interacts with members of 
the T cell factor/lymphoid enhancing factor (TCF/LEF) transcription factor family to enhance 
expression of their target genes [146], which in turn regulate cell proliferation, carcinogenesis, 
differentiation, embryonic patterning, and stem cell maintenance [154–156].  
The effects of Wnt signaling, however, have been shown to be highly tissue-specific and Wnt-specific. 
In the case of hair follicle stem cells in the skin, signaling through Wnt1 activated stem cell 
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hyperproliferation via an mTOR-dependent mechanism, but long-term this activation of mTOR led to 
stem cell exhaustion and senescence [147]. This finding led the authors to conclude that while Wnt 
signaling can be a potent stimulus for stem cell proliferation, prolonged mTOR activation may serve as 
a protective mechanism to prevent tumor formation. The cost of this, of course, is exhaustion and 
depletion of that stem cell pool, ultimately resulting in impaired regeneration and aging of the tissue. 
In patients with acute myeloid leukemia, aberrant Wnt/β-catenin signaling, which controls self-renewal 
in the HSC pool, was higher in patients with unfavorable karyotypes and predicted a shortened 
survival [157]. 
In HGPS the tissue-specific patterns of accelerated aging point to a defect in MSC function. The 
defect in this adult stem cell compartment has been shown to be the result of both impaired  
self-renewal and dysregulated differentiation resulting from aberrant Notch and Wnt signaling [158]. 
Disruption of the nuclear lamina by progerin was shown to be directly responsible for downstream 
activation of Notch signaling effectors, spurring uncontrolled sporadic differentiation of MSCs along 
all three germ layers and enhanced osteogenesis at the expense of adipogenesis when differentiation 
was directed [159]. Wnt signaling was found to be severely disrupted in the progeroid Zmpste24−/− 
mouse model (deletion of this enzyme causes restrictive dermopathy in humans), where the absence of 
normal lamin A resulted in an absence of active nuclear β-catenin in follicular stem cells, leading to 
down-regulation of cyclin D1 and repression of Akt and mTOR activation [160].  
Further work has shown that LEF1 is down-regulated as a result of this impaired nuclear 
translocation/retention of β-catenin; the absence of this transcription factor-activator complex in adult 
cells markedly reduced activation of canonical Wnt targets [161]. In this setting of severe Wnt 
inhibition, stem cells were not reduced in number, but instead entered a senescent state earlier and 
failed to proliferate, resulting in exhaustion of the functional stem cell compartment. The authors of 
this study also discovered increased apoptosis of the support cells in the stem cell microenvironment, 
which they suggested is another negative impact of defects in critical fate-determining signaling 
pathways that enable communication between tissue-resident stem cells and their niches. 
Another mouse model of accelerated aging also points to aberrant Wnt signaling as a causative 
factor in degeneration due to stem cell defects, but from a different perspective. The Klotho mouse, 
which lacks klotho, a transmembrane and secreted β-glucuronidase involved in regulating insulin 
sensitivity among other functions, displays an accelerated aging phenotype, including short lifespan, 
infertility, arteriosclerosis, skin atrophy, osteoporosis, and emphysema [162]. Analysis of tissue-resident 
stem cells from multiple organs in Klotho mice revealed that they were reduced in number and displayed 
abundant senescence-associated markers prematurely [163]. Klotho was found to be a secreted Wnt 
antagonist capable of binding Wnts1, 3, 4, and 5a, and over-activation of Wnt signaling in Klotho mice 
drove tissue-resident stem cells into an early senescent phenotype, resulting in lack of self-renewal and 
stem cell compartment exhaustion.  
Taken together with findings regarding aberrant Wnt signaling in the Zmpste24−/− mouse, these 
studies reveal the exquisite sensitivity of adult stem cell pools to the fate-determining effects of Wnt 
signaling, too much or too little of which results in failed maintenance of quiescent progenitors in 
adulthood. Perturbation of this pathway one way or the other has been demonstrated to result in adult 
stem cell aging and exhaustion, along with impaired differentiation, in the muscle compartment [164], 
the hematopoietic compartment [165,166], the vasculature [161], and the skeletal system [161,167] in 
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addition to the skin, the gut, and the kidney. It is suspected that these processes unfold in normal aging 
as well as accelerated aging phenotypes, especially given the accumulation of low levels of progerin 
over time in normal individuals and declining serum levels of klotho in human aging [168]. 
5.2. The FoxO Family: Stem Cell Stress Response and Indirect Effects 
Another mechanism leading to altered Wnt signaling in aging is a shift in β-catenin binding to favor 
FoxO transcription factor signaling over the canonical Wnt pathway, mediated by TCF/LEF 
transcription factor signaling, in response to increasing oxidative stress. The FoxOs are a family of 
transcription factors regulating several of the previously discussed intersecting pathways, and have 
been shown to coordinate cell response in tumor suppression, metabolism, and organismal longevity 
(reviewed in [2,169,170]). In this capacity FoxO signaling acts to resist cellular stress opposite the 
growth-promoting signaling of mTOR [171]. FoxO transcription factors are downstream targets of 
insulin, growth factors, and nutrient and oxidative stress stimuli and in turn regulate several 
fundamental processes, depending on the cell type, including gluconeogenesis, neuropeptide secretion, 
cell cycle arrest, atrophy, autophagy, apoptosis, and stress resistance [169,172,173] (Figure 3, [173]). 
Furthermore, the FoxOs are an interesting family of transcription factors in that several are 
ubiquitously expressed, but display both highly specialized and universal functions in distinct cell 
types, as well as distinct and redundant functions which can be attributed to different FoxOs within the 
same cell type [2]. 
Figure 3. Roles of FoxO transcription factors in cells and in the organism. FoxO 
transcription factors trigger a variety of cellular processes by upregulating a series of target 
genes (in italics). The cellular responses elicited by FoxO affect a variety of organismal 
processes, including tumor suppression, longevity, development and metabolism. Reprinted 
by permission from Macmillan Publishers Ltd.: Oncogene [173], copyright 2008. 
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Studies on the effect of oxidative stress on adult stem cells suggest that it drives a shift in binding  
of the cellular β-catenin pool from the TCF/LEF family to the FoxO family [2,145,174]. As a cofactor 
in FoxO-mediated transcription, β-catenin facilitates defense against oxidative and other cellular 
stresses [175–177]. Diversion of β-catenin binding from TCF/LEF to FoxO, combined with inhibitory 
feedback to β-catenin/TCF signaling, serves to diminish canonical Wnt signaling [145,146,178,179]. 
This redirection of β-catenin function secondary to oxidative stress and resulting change in the cell’s 
transcriptional program have been implicated in several aging-related disease processes and cell 
senescence [97,146,149]. This transcriptional shift is particularly important in osteoporosis, where 
canonical Wnt signaling in osteoblasts is critical for skeletal homeostasis. This is one example of how 
increased activation of FoxO signaling by oxidative stress accumulated with age serves to directly 
undermine maintenance of an entire organ system, independent of the more broadly discussed  
“oxidative hypothesis of senescence”, wherein reactive oxygen species drive cells into arrest by 
activating FoxO signaling. 
FoxO1 is of particular importance in age-associated skeletal disease. Osteoporosis, for example, is 
characterized by decreasing bone mass, which is attributed both to declining numbers of osteoblasts 
and declining function of osteoblasts. FoxO1 is critical for regulating osteoblast proliferation in the 
face of age-related oxidative stress and declining resistance to the effects of oxidative stress, both 
through its regulation of protein synthesis via interaction with the osteoblast-specific transcription 
factor ATF4 and through suppression of stress-induced p53 signaling which would otherwise lead to 
cell cycle arrest [180]. 
Several FoxOs regulate organismal metabolic function and thus play a role in metabolic diseases of 
aging and resistance to those diseases. FoxO1, through its regulation of osteocalcin secretion by 
osteoblasts, impacts pancreatic β-cell proliferation, insulin secretion, and insulin sensitivity [181].  
In the case of atherosclerosis and vascular diseases of aging, FoxOs are important downstream 
effectors of PI(3)K, AMPK, and c-Jun N-terminal kinase (JNK) signaling. In the endothelium FoxO1 
serves as a negative regulator of angiogenic behavior; this suppressive function, which is enhanced by 
activities of FoxO3 and FoxO4, is critical for organized vessel growth during development and  
repair [84]. FoxO1, FoxO3, and FoxO4 are also required to maintain endothelial quiescence within 
healthy vessels, and formation and remodeling of the endothelial barrier function is regulated by 
FoxO1 in a β-catenin-dependent manner. 
FoxO transcription factors also play a role in attenuating diseases of aging through their regulation 
of the immune system and its progenitor pools (reviewed in [182]). In general, FoxOs regulate 
survival, cell cycle progression, and resistance to stress in immune progenitors and differentiated 
immune cells, as they do in many other cells types, consistent with a decline in overall immune 
function and proliferative capacity of the HSC pool with aging. FoxO transcription factors also 
regulate immune activity via specialized functions in different cell types. FoxO1 specifically regulates 
development and trafficking of B and T lymphocytes through several mechanisms, including survival 
and homing of pre-B cell and naive T cells in response to growth factor receptor regulation, pre-B cell 
maturation by induction of Rag genes and B cell receptor recombination, and B cell class-switch 
recombination and somatic hypermutation in response to germinal center formation.  
FoxO3 has been extensively studied in the immune system, and regulates not only lymphocyte 
function, but also innate immunity. Like FoxO1, FoxO3 regulates T and B lymphocyte survival and 
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cell cycle progression, but FoxO3 additionally controls survival and entry of memory T cells into a 
quiescent state, critical for later response to infection. This particular function of FoxO3 is of great 
interest in the human immunodeficiency virus (HIV) field, as inhibitors of FoxO3 might be used to 
prolong survival of memory T cells during chronic HIV infection. FoxO3 also has similar roles in B 
cells, and is likely important for terminating immune responses to infection, and possibly for controlling 
lymphocyte responses that would result in autoimmunity. FoxO3 also has critical specific regulatory 
functions in innate immune cells: Controlling the number of neutrophils, monocyte/macrophages, dendritic 
cells (DCs), and erythrocyte progenitors (in opposition to erythropoietin signaling); directing neutrophil 
migration; and regulating inflammatory cytokine secretion by DCs in response to coinhibitory 
molecules [2,182]. Immune-specific functions of FoxO transcription factors, including the examples 
outlined here, are not well understood in the context of aging and increased metabolic stress, but may 
also contribute to the overall decline of cell-specific immunity observed in elderly individuals, 
including decreased maintenance of the HSC pool, increased susceptibility to infection, reactivation of 
latent viruses, and decreased immune surveillance with respect to cancer. 
6. Mechanisms of Stem Cell Aging: Lessons from Transcriptional Reprogramming  
In addition to their place on a spectrum of proliferative capacity, stem cells also exist on a spectrum 
of differentiation bounded by terminally differentiated unipotent effector cells at one extreme and 
pluripotent embryonic stem cells (ESCs) at the other [183]. Pluripotent cells, which can differentiate to 
any cell in the body, are thought to be extremely rare in adult mammals. Much work has investigated 
directed epigenetic manipulation of cell fate, inducing a cell to follow a completely different 
transcriptional program and as a result shift to an entirely different phenotype and spectrum of activity.  
The recent development of nuclear reprogramming methods used to generate iPS cells has created 
new opportunities for regenerative medicine using stem cells, but the mechanisms underpinning cell 
reprogramming remain incompletely understood, and many areas where stem cell manipulation can 
enhance regenerative medicine have yet to be explored [184,185]. Introduction of a cocktail of 
pluripotency-maintaining transcription factors, likely in combination with a series of stochastic 
epigenetic events, can direct terminally differentiated cells to revert to a state similar to that of an  
ESC [184,186–189], resulting in iPS cells that are pluripotent and germ-line competent, and exhibit the 
capacity for chimerism and teratoma formation and a gene expression profile characteristic of  
ESCs [190].  
The exact nature of the pluripotency induction steps that take place during and subsequent to the 
expression of the exogenously transduced reprogramming transcription factors is an active area of 
research. Whether the two key “stemness” features of iPS cells, i.e., proliferative capacity and  
multi-lineage differentiation potency, arise from specific epigenetic events during the reprogramming 
process and result from the synergistic action of more than one of the reprogramming factors is 
unknown. Full reprogramming, i.e., the production of iPS cells, requires a minimal period of 
expression of these reprogramming transcription factors; this period was discovered by Yamanaka’s 
group to be significantly longer for induction of pluripotency in human cells compared to mouse cells, 
taking approximately three weeks [189]. Recent studies have also focused on the screening of small 
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molecules capable of reprogramming [191,192], with one group achieving successful reprogramming 
using a combination of seven compounds [193].  
6.1. Partial Reprogramming 
However, iPS cells do not make ideal starting material for regenerative medicine or cell  
therapy [194]. Like ESCs, it is technically challenging to direct them to undergo exclusive 
differentiation along a specific cellular lineage, and they exhibit a shift in the self-renewal spectrum 
that confers a high risk of carcinogenesis, frequently forming tumors in animals [190,195]. It is 
possible that in the future we may be able to achieve partial reprogramming, resulting in the acquisition 
of renewed proliferative capacity and an increased differentiation lineage potential, but without other 
characteristics of ESCs and fully reprogrammed iPS cells, such as the capacity for chimerism and 
teratoma formation. 
Partial reprogramming is the process of moving an adult cell on the spectrum of differentiation from 
limited multipotency toward pluripotency, without returning it to the completely pluripotent state of an 
ESC. Several groups are engaged in studying how partial reprogramming can most effectively be 
induced in adult stem cells, how it alters the transcriptional program and phenotype of adult stem cells, 
and how this approach may be used to preserve the potency, proliferative capacity, and regenerative 
utility of adult stem cells as they are cultured in vitro (reviewed in [196]). Observations from 
Yamanaka’s work in mouse cells suggests that selection based on expression of FBX15 yields partially 
reprogrammed iPS cells [197]. The definition of partial reprogramming described in that work was that 
partially reprogrammed iPS cells formed teratomas but lacked the ability to generate adult chimeric mice.  
A lesser degree of partial reprogramming has been described in umbilical cord blood cells cultured 
in medium supplemented with FGF4, SCF, and FLT-3 ligand [198]. These cells exhibited increased 
binding of acetylated histones H3 and H4 at the OCT4 promoter and upregulation of OCT4 and Nanog 
expression, but their reprogramming was considered a partial event because they exhibited DNA 
hypermethylation in the OCT4 gene region, and continued H3 and H4 acetylation at promoter regions 
for markers of terminal differentiation. Other studies have achieved partial reprogramming by 
administration of growth factors or transcription factors to redirect a non-pluripotent progenitor cell to 
a pluripotent phenotype [198–200]. Growth factor-induced partial reprogramming has been used to 
enhance plasticity in peripheral blood monocytes and subsequently to convert them to immature β 
endocrine cells [199]. During the observed limited life span of increased plasticity, these cells 
exhibited up-regulation of pluripotency markers.  
Recently some groups have undertaken to “directly reprogram” or transdifferentiate cells from one 
terminally differentiated phenotype to another using both developmental and lineage-specific transcription 
factors for therapeutic application in specific organ systems [201–209]. Partial reprogramming is a 
potentially promising approach to confer some of the desirable properties of ESCs onto adult  
stem cells or terminally differentiated effector cells, but it is evident that controlling partial 
reprogramming and resulting changes in potency requires a more complete understanding of 
underlying regulatory mechanisms.  
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6.2. Molecular Mechanisms of Reprogramming 
Discovery of mechanisms by which reprogramming events redefine the transcriptional program in 
adult cells, particularly signaling related not only to potency, but to telomere maintenance, oxidative 
stress, and senescence, will aid in generating techniques to increase the longevity of the adult stem cell 
in culture and preserve those cells in vivo [210–215]. Regulation of stem cell pluripotency and 
differentiation has been studied at the transcriptional and epigenetic level in ESCs, particularly mouse 
ESCs [216–223]. High-throughput sequencing methodologies are now used to characterize whole 
networks of regulation in ESCs [224,225] and analyze the roles of overlapping and interactive 
regulatory networks in determining stem cell fate, including the role of microRNAs [226] and 
epigenetic marks (reviewed in [227]).  
Regulatory networks in reprogrammed cells are also now being studied using genome-wide 
analytical tools, and initial results from studies of iPS cells derived from aged individuals suggests that 
reprogramming can undo many, though not all, effects of age (reviewed in [228]). SIRT1, critical for 
maintenance of stemness in multiple types of adult stem cells, is post-transcriptionally up-regulated 
during the reprogramming process [91]. Reprogramming of aged HSCs to iPS cells with subsequent 
re-derivation of HSCs showed comparable function to endogenous blastocyst-derived HSCs in marrow 
reconstitution assays [229]. Perhaps the most critical lesson regarding stem cell aging and loss of  
self-renewal gleaned from reprogramming research has been that cell aging as we know it is a  
largely reversible process, characterized not by permanent genetic mutations so much as progressive 
epigenetic inflexibility.  
7. Mechanisms of Stem Cell Aging: Lessons from Reprogramming Efficiency Studies 
Studies of transcriptional reprogramming efficiency have proven very instructive in the area of 
methods for enhancing cell stemness and overcoming senescence. Several pathways controlling onset 
of cellular senescence must be differentially regulated to achieve reprogramming, including telomerase, 
p53, and mitochondrial/oxidative stress pathways [230]. Telomere length as a measure of cellular 
aging has revealed interesting differences between reprogrammed pluripotent cells and their embryonic 
counterparts. Many widely used human iPS cell lines derived from somatic cells display prematurely 
aged telomeres compared to hESCs with accompanying differential regulation of genes regulating 
telomere length. iPS cell clones derived from an hESC-derived mortal clone (for isogenic comparison) 
largely followed the same pattern with the exception of one clone spontaneously displaying levels  
of telomerase activity comparable to the parent hESC line, with maintenance of longer telomere length 
in culture [231]. From this finding we have learned that current reprogramming methods do not  
always result in iPS cells where the aging process has been fully reversed, but that further—likely 
stochastic—epigenetic events can enable full reversal of cell aging.  
Discovery of those specific events that result in maintenance of long telomeres is a relatively 
focused research problem that is likely solvable with the massive generation of transcriptional network 
data currently underway. Comparative studies of reprogramming in aged cells from multiple organs in 
mice have thus far demonstrated that age is an impediment to efficient reprogramming. However, 
many groups have successfully generated bona fide iPS cells from somatic cells of aged human 
J. Clin. Med. 2014, 3 108 
 
 
subjects [228], and with ever-improving techniques have even demonstrated comparable reprogramming 
efficiency in fibroblasts from young versus old patients [232]. 
Reprogramming Efficiency and Metabolic Stress 
With respect to oxidative stress and mitochondrial function, the observation has been made that iPS 
cells rely on a Warburg-type switch to glycolytic metabolism. During reprogramming of fibroblasts to 
iPS cells, repression of H+-ATPase and up-regulation of the lipogenic enzymes acetyl-CoA carboxylase 
and fatty acid synthase is observed, as is the case in cells from many types of cancer, and inhibition of 
these lipogenic enzymes greatly decreases reprogramming efficiency [233]. Studies of mitochondria 
within human iPS cells have revealed that they revert to an immature state similar to those of an ESC, 
complete with reduced oxidative damage, contributing significantly to rejuvenation of the cell [228,230]. 
Pharmacologic induction of autophagy has also been shown to enhance reprogramming efficiency, 
perhaps through elimination of older, damaged mitochondria [88].  
Metformin, an AMPK activator, has been shown to decrease reprogramming efficiency in multiple 
studies [119], despite the fact that AMPK activation induces endogenous antioxidant expression and 
reduces intracellular reactive oxygen species [234]. When activated, AMPK, which functions as a 
master sensor and regulator of intracellular changes in energy status, prevents transcriptional activation 
of OCT4 (though not other reprogramming transcription factors) and prevents somatic cells from 
making the energetic switch to glycolysis, thereby effectively blocking reprogramming [119].  
This is highly instructive for two reasons. First, the malignant component of teratomas derived from 
implanted iPS cells are driven by OCT4, and application of metformin to iPS cells (after reprogramming) 
has been used to suppress or block entirely the formation of iPS-derived teratomas [126], suggesting 
that this well characterized FDA-approved drug might enable clinical application of iPS cells without 
risk of carcinoma.  
Second, studies on the effects of metformin and other AMPK activators such as  
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) on the reprogramming process have 
illuminated a critical path to achieving pluripotency: appropriation of energetic capital. It has long 
been known that many types of stem cells are able to survive in harsh, energetically unfavorable 
conditions such as hypoxia because of their ability to rely heavily on glycolysis (provided they are not 
calorically restricted), but the discovery that a particular metabolic phenotype is required for 
supporting the energetic requirements of the reprogramming process has resulted in the understanding 
that being able to readily shift to a glycolytic metabolic phenotype is a defining property of stem cells. 
The implications of these findings to the study of stem cells in aging are enormous, because 
manipulating the metabolic phenotype of a cell as a strategy to restore its function is an  
approachable problem. 
Ascorbate, a potent antioxidant, has been shown to accelerate the kinetics of reprogramming and to 
alleviate cell senescence by reducing levels of p53 [235]. Curcumin, another antioxidant, has been 
shown to have similar effects on reprogramming efficiency [236]. It is possible that ascorbate enhances 
reprogramming in part through reduction of reactive oxygen species, but more likely by increasing the 
rate of transcriptome changes through other mechanisms: It is a cofactor for several enzymes, including 
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collagen prolyl hydroxylases, HIF (hypoxia-inducible factor) prolyl hydroxylases, and histone 
demethylases [237], and may facilitate histone demethylation.  
Epigenetic modifiers, such as valproic acid, have been shown to enhance reprogramming efficiency, 
either alone or in combination with antioxidants. This further supports the idea that enabling histone 
demethylation confers epigenetic flexibility and enhances the ability of the cell to dramatically shift its 
transcriptional program [235]. Regulation of senescence and metabolic state through the mTOR hub 
seems to be of particular importance during reprogramming and is a pathway that can be fine-tuned to 
direct cell fate (reviewed in [238]). mTOR inhibitors, such as rapamycin and resveratrol (which is also 
a sirtuin activator), are known to slow cellular senescence in response to DNA damage by limiting the 
accumulation of p16 and p21, thereby enabling entry into a reversible quiescent state rather than an 
irreversible senescent state. These same compounds have been shown to increase the efficiency of 
reprogramming, in addition to other sirtuin activators, antioxidants, autophagy inducers, and PI(3)K 
inhibitors [236]. Interestingly, although it enhances reprogramming of normal somatic cells, resveratrol 
inhibits the stemness, epithelial-mesenchymal transition, and metabolic reprogramming of cancer stem 
cells to glycolysis through activation of p53, again highlighting the innate differences between the 
molecular circuitry of normal stem cells and cancer stem cells, a finding that can potentially be 
exploited for therapeutic purposes [239]. 
8. Therapeutic Approaches under Investigation 
Given the growing evidence that many diseases of aging may reflect adult stem cell exhaustion, it is 
not surprising there is great interest in restoring adult stem cell function to ameliorate these conditions 
and regenerate aged tissues [23]. Adoptive transfer of fetal MSCs into adult mice has been shown to 
extend median lifespan of the animals [240]. Adult stem cell mobilization and transplant are two 
obvious strategies that have achieved moderate success for certain types of injury and disease in 
humans, and many types of adult stem cells have been utilized for this purpose [241]. MSC cellular 
therapy has proven to be safe for a number of vascular disorders, such as coronary artery disease, 
peripheral vascular disease, erectile dysfunction, and stroke, and is an attractive option for patients 
who are poor surgical candidates [242–246].  
Despite these successes, the problem remains that adult stem cells from elderly donors, the very 
people who most frequently require enhanced peripheral stem cell function for tissue repair, undergo 
changes in their functional capacity as a result of aging (reviewed in [104]). This decline in functional 
capacity, therefore therapeutic utility, has been combatted using some surprisingly simple interventions: 
Conditioning with hypoxia prior to transplant, for example, has been extensively documented as 
effective for reducing reactive oxygen species production by adult stem cells and improving their 
therapeutic efficacy in many in vivo ischemia and other disease models [247–249]. This has proven 
sufficient to counteract the impaired oxidative stress resistance of MSCs from elderly donors [78].  
Likewise, the use of naturally occurring antioxidant polyphenols, such as curcumin, has been 
documented to suppress inducible oxidative stress in human MSCs ex vivo and may prove to be a safe 
method for reducing oxidative damage to the in vivo MSC pool [250]. Rejuvenation of aged human 
MSCs has been achieved by seeding cell scaffolds with proangiogenic growth factors, resulting in 
improved functional capacity of the aged cells after implantation into an infarcted rat heart compared 
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to aged cells seeded on untreated scaffolds [251]. Systemic administration of growth factors has also 
proven effective for restoring aged MSCs in vivo; in the case of senile osteoporosis, intraperitoneal 
injections of rhBMP2 were sufficient to reverse the osteoporotic phenotype, and this effect was 
mediated by an expanded MSC pool displaying increased proliferation and decreased apoptosis [252].  
Ex vivo genetic modification has also been used to overexpress rejuvenating factors in aged bone 
marrow- and adipose-derived MSCs prior to therapeutic delivery. Transplantation of aged MSCs 
overexpressing telomerase and/or myocardin was more efficacious in stimulating arteriogenesis and 
blood flow in a limb ischemia model than transplantation of control aged MSCs [253]. A similar study 
achieved increased angiogenesis and less adverse matrix remodeling in a rat model of myocardial 
infarction using aged MSCs transfected with TIMP3 or VEGF [254].  
8.1. Transcriptional Reprogramming 
The idea has been raised that it might be possible to exploit reprogramming techniques for renewal 
of the in vivo stem cell pool to combat diseases of aging [255]. While full reprogramming of stem cells 
in vivo to restore tissues degenerated as a result of age is not likely to manifest clinically until highly 
efficient reprogramming can be achieved through delivery mechanisms other than lentiviral vectors, 
the idea of “direct reprogramming” of cell fate in specific tissues in vivo has been pursued using 
developmental regulators that redirect a cell’s terminally differentiated state rather than returning the 
cell to a pluripotent state—what is known in the adult stem cell world as transdifferentiation, as 
opposed to dedifferentiation. This approach has been employed successfully to convert pancreatic exocrine 
cells to endocrine cells, rescuing the hyperglycemic phenotype in a mouse model of diabetes [256].  
Generation of stem cells resistant to the phenotypic changes that accompany replicative senescence, 
such as arrested proliferation and decreased differentiation potential, would create a more ideal cell 
type for use in stem cell-based tissue engineering and cell therapy. Ex vivo reprogramming to achieve a 
kind of cell “reset” may in the future yield this improved cell source. iPS cells generated from HGPS 
patient fibroblasts display no evidence of progerin accumulation, nuclear envelope and epigenetic 
defects, or accelerated aging, suggesting this approach can in fact be used to reset an aged cell [58].  
In the case of HGPS-iPS cells, differentiation results in the rapid accumulation of progerin and 
restoration of the accelerated aging phenotype [257].  
However, this would not be an issue with physiologically aged donor cells. iPS cells derived from 
young and old non-progeroid human fibroblasts displayed no differences in mitotic activity after 
differentiation back to a fibroblast phenotype, suggesting that reprogramming is a successful approach 
to reset aged cells to a youthful phenotype in physiologically aged donors. In this study an excisable 
vector was used, further illustrating what might be a feasible approach to ex vivo rejuvenation of aged 
cells [232]. 
Stem cell rejuvenation techniques are also needed in situations where it is preferable to use  
cells from a specific donor who happens to be of advanced age, since HSC donor age is correlated  
with adverse events after infusion [258]. Meeting this need is critical for transplants with autologous  
or human leukocyte antigen (HLA)-matched sibling HSCs from elderly donors, which result in better 
outcomes in leukemia and lymphoma than HSCs from an HLA-matched unrelated younger  
donor [259]. Several groups have investigated the use of reprogramming transcription factors to restore 
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differentiation potential and proliferative capacity of adult stem cells from aging donors. In one such 
study, Nanog was over-expressed in adult marrow-derived MSCs, resulting in reversal of lost 
myogenic differentiation potential and enhancement of proliferation comparable to that observed in 
neonatal marrow-derived MSCs [260]. It remains to be seen if other approaches to dedifferentiation 
will restore an unblemished phenotype to cells to the same degree that reprogramming appears to.  
8.2. Calorie Restriction and Pharmacologic Mimicry of Calorie Restriction 
Calorie restriction as a therapeutic intervention to delay aging and extend lifespan has been 
extensively studied in animal models but, at levels that would confer significant clinical benefit, is 
unlikely to gain much traction due to low rates of adherence. Pharmacologic agents to reduce nutrient 
intake or absorption might be employed to this end (reviewed in [261]). The effects of diet and 
exercise to reduce body weight and correct metabolic disease on adult stem cell populations are 
unknown, although reduction in visceral fat has been shown to correct endocrine functions of adipocytes. 
Enhancement of PPARδ signaling has been suggested as an adjunct therapy to boost catabolism  
in visceral adipose tissue, perhaps in part through differentiation of adipose-resident MSCs to 
mitochondria-enriched small adipocytes [261]. To this end PPARδ agonists have been tested in clinical 
trials, but despite protective effects against obesity and diabetes, development was discontinued due to 
multi-organ cancer formation in animal models [262,263].  
Other studies have investigated the use of pharmacologic agents to mimic the molecular benefits of 
calorie restriction for extending lifespan and healthspan (Figure 4, [264]). A recent report described 
extension of lifespan and healthspan in male mice with administration of metformin beginning in 
middle age [265]; past work has established this same phenomenon in invertebrates [266]. At the 
cellular level, treated mice displayed increased AMPK activity, decreased oxidative damage, and a 
transcriptomic shift mimicking the effects of calorie restriction. As a result the mice maintained 
sensitivity to insulin and low levels of systemic inflammation into old age.  
It should be noted that the dose of metformin used to achieve these effects resulted in serum drug 
levels an order of magnitude higher than what is typically achieved in patients when the drug is used as 
an antidiabetic therapy; a ten-fold higher dose proved toxic rather than beneficial in this study. As is 
the case for many pathways regulating longevity, cellular aging, and oncogenic resistance, the degree 
to which AMPK signaling is altered is likely to require a fine balance between too much and too little. 
This, combined with concerns about the pleiotropic effects of metformin in vivo which manifest 
differently with short-term versus long-term use, means that significant work is still needed before this 
potentially attractive therapy for systemic anti-aging can be safely employed. 
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Figure 4. The growth hormone (GH)—insulin-like growth factor I (IGF1) pathway and its 
signaling cascade, which involves PI(3)K and Akt, can modulate longevity and cancer in 
model systems. Calorific restriction inhibits GH-IGF1 signaling and can also inhibit mTOR 
and activate AMP-activated protein kinase (AMPK) and sirtuin 1 (SIRT1). Interactions 
between components of these pathways, and with SIRT1, remain incompletely understood. 
The role of SIRT1 in modulating mammalian ageing has not been demonstrated, and it 
seems to have a dual role in cancer. DNA repair systems and DNA damage checkpoints 
prevent the DNA damage accumulation that contributes to cancer and ageing, although 
possibly through different cellular mechanisms. Reprinted by permission from Macmillan 
Publishers Ltd.: Nature Reviews Cancer [264], copyright 2013. 
 
8.3. Epigenetic Modification 
The emerging field of translational epigenetics is aimed at correcting heritable but potentially 
reversible “epimutations” with chemical modifiers, and is gaining some traction in diseases of aging 
such as metabolic syndrome (reviewed in [267]) and cancer (reviewed in [268]) because it offers the 
possibility of targeting some of the same cell processes as transcriptional reprogramming without the 
associated risks of introducing exogenous genetic material. The treatment of epigenetically disrupted 
stem cells in cancer in particular may yield tremendous clinical benefit as the number of epigenetic 
modifiers grows, allowing for more specific targeting of known associated epimutations.  
In the area of metabolic disease, epigenetic modification with nucleic acids or small molecules may 
allow for extending the healthspan if not the lifespan of patients. The demethylase UTX-1, the activity 
of which increases in mid-life, removes gene inactivating marks such as histone H3 trimethylation on 
lysine 27 (H3K27me3) on members of the insulin/IGF-1 signaling pathway, enhancing their activity 
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and resulting in decreased FoxO activity and age-related cellular decline. Restoration of H3K4me3 on 
an insulin-like receptor gene in C. elegans has been shown to decrease insulin/IGF-1 signaling, 
resetting the cell to a more naive epigenetic state and ultimately extending the life of the animal by 
30% [139]. Although this effect was achieved through the use of RNA interference, the authors 
expressed optimism that in the near future small molecules might be employed to target epigenetic 
marks and/or modifying enzymes in a similarly specific strategy.  
Similarly, the histone methyltransferase SUV39H1 is protected from proteasomal degradation by 
enhanced binding to progerin in Zmpste24−/− mice, resulting in increased H3K9me3 levels and 
compromised genome maintenance, which leads to accelerated senescence [269]. Targeting of 
SUV39H1 in this study resulted in amelioration of the progeroid phenotype in Zmpste24−/− mice, 
including reduction of bone loss and extension of lifespan by 60%, suggesting a similar strategy might 
be useful in the context of normal aging.  
In an analogous approach, H4K16 hypoacetylation was targeted in the same mouse model to 
ameliorate the progeroid phenotype, with overexpression of the histone acetyltransferase Mof or 
addition of the histone deacetylase inhibitor sodium butyrate to drinking water promoting repair of 
damaged DNA and resulting in reduced evidence of disease [270]. Hypoacetylation of this mark was 
also found in aged wild-type mice, suggesting that aberrant histone acetylation may play a role in 
physiologic aging and administration of histone deacetylase (HDAC) inhibitors may have therapeutic value 
in disease of aging. 
8.4. Strategies to Delay Senescence 
Genetic modification strategies have specifically targeted known regulators of senescence and 
lifespan to combat diseases of aging. Preventing senescence, clearing senescent cells, or interfering 
with the senescence-associated secretory phenotype, in which cells release inflammatory mediators 
such as cytokines and matrix metalloproteinases, are all approaches that might lessen the contribution 
of cellular aging to chronic illness [271]. Given the complexity of the signaling crosstalk regulating 
senescence and associated events, identification of therapeutically targetable elements in this  
network—the “senectome”—is proceeding at multiple levels, the most recent of which includes 
senescence-associated micro-RNAs, which could be manipulated or used as clinical biomarkers [272].  
In non-healing diabetic skin ulcers, siRNA- or vivo-Morpholino antisense-based gene therapy 
targeting of CAV1 or PTRF, which are both turned on by oxidative stress in diabetic fibroblasts and 
induce p53-dependent premature senescence, inhibited senescence and accelerated ulcer repair [273]. 
Atherosclerosis, especially in the context of type 2 diabetes, is related to endothelial senescence and 
has been reduced using a variety of interventions targeting nitric oxide levels and bioavailability in the 
endothelial microenvironment, including eNOS gene therapy [274]. Gene therapy to induce telomerase 
activity in CD8 T cells, which undergo premature senescence in the context of HIV infection, results in 
enhanced proliferation and increased antiviral function [275]. While preliminary research in this area 
has not resulted in karyotypic changes or wildly altered growth kinetics of the CD8 compartment, the 
authors of this study emphasized the need for pharmacologic approaches that would mimic these 
effects without the need for TERT gene therapy due to the obvious risks.  
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The use of pharmacologic agents to modulate senescence-associated pathways is a promising 
avenue to counteract the effects of aging in the clinic. Mice of both genders treated with rapamycin 
starting in mid to late life display extended lifespan and reduced incidence of cancer [276]. Treatment 
of cells from HGPS patients with rapamycin, results in enhanced clearance of the mutant protein 
progerin by autophagy and delayed onset of senescence [277]. Conversely, activation of Akt-mTOR 
signaling through inhibition of isoprenylcysteine carboxyl methyltransferase, the enzyme which 
processes prelamin A to lamin A and enables trafficking to the nuclear rim, in Zmpste24−/− mice also 
delayed onset of senescence and improved disease phenotype. This suggests the Akt-mTOR axis, like 
the Wnt axis, is finely tuned and must be carefully manipulated to achieve therapeutic benefit [278]. 
Rapamycin is unlikely to be utilized extensively as an anti-aging therapeutic due to its side effects, 
which include hyperlipidemia and immunosuppression; however, newer analogs of rapamycin 
(rapalogs) are in development and may find use as anti-aging compounds, along with other agents that 
inhibit mTOR (reviewed in [279]).  
Pharmacologic activation of SIRT1 in a rat model of diabetes restored endothelial differentiation, 
pro-angiogenic chemokine secretion, and in vivo angiogenic activity of bone marrow-derived early 
outgrowth cells to that of cells from control animals [280]. Pharmacologic blockade of angiotensin II 
signaling through its type I receptor, which is used clinically to lower blood pressure and prevent 
insulin resistance in metabolic syndrome, also inhibits adipogenesis in adipose- and bone marrow-derived 
MSCs, both preventing further pathologic expansion of adipose tissue and helping to maintain an 
uncommitted progenitor pool for tissue homeostasis and repair [281]. In opposition to the enhanced 
production of 20-HETE by the cytochrome P450 system observed in metabolic syndrome, MSCs 
generate P450-derived epoxyeicosatrienoic acids (EETs) from arachidonic acids, and when administered 
exogenously these lipid mediators have been shown to decrease adipocyte differentiation of MSCs via 
an increase in heme oxygenase-1 and decrease in PPARγ, C/EBPα, and Fas and to reprogram adipocyte 
stem cells to a new phenotype displaying a smaller cell size, increased secretion of adiponectin, and 
decreased secretion of inflammatory cytokines [282]. EET agonists have also been shown to reverse a 
metabolic syndrome phenotype in an obese animal model, highlighting the therapeutic potential of 
targeting production of these molecules in the adult stem cell pool to combat this age-related disease 
phenotype in humans [283]. 
Given the complex and sometimes unpredictable nature of these emerging pharmaceutical and 
genetic approaches to age-related disease therapy, sometimes the simplest approaches to maintaining 
health are best. In the lifelong struggle between growth-promoting signaling pathways and stress 
resistance pathways, sleep has a critical place in determining the balance [171]. mTOR and FoxO 
signaling are turned on in distinct temporal windows during early and late sleep, respectively, in 
response to alterations in somatotrophic signaling, suggesting that a good night’s sleep truly does have 
restorative powers. Adult stem cells have been demonstrated to undergo significant circadian 
regulation in multiple studies, with HSCs, marrow- and adipose-derived MSCs, and cancer stem cells 
all subject to transcriptome modulation by core circadian regulatory proteins (reviewed in [284]). 
ESCs, in contrast to adult stem cells, are not subject to circadian regulation and have been shown to 
acquire molecular circadian oscillation upon differentiation; subsequent transcriptional reprogramming 
with Sox2, Klf4, Oct3/4, and c-Myc genes was shown to suppress circadian cycling, literally resetting 
the internal clock in the resulting iPS cells [285]. Interestingly, action of core circadian regulatory 
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proteins on physiologic cellular processes is opposed by SIRT1 with aging (reviewed in [286]), and 
control of central circadian cycling by SIRT1 in the brain decays over time [287]. In general circadian 
rhythms break down with age, coinciding with the development of metabolic derangements and 
potentially contributing significantly to the organismal aging process (reviewed in [288]). Research 
into the impact of macro-environmental factors, such as organismal circadian rhythms, on stem cell 
niches may open new therapeutic avenues for manipulating stem cell fate in diseases of aging [289]. 
As therapeutic approaches go, good sleep hygiene is safe and free from side effects, cost-effective, and 
potentially contributes more than we currently know to the long-term maintenance of adult stem  
cell compartments. 
9. Conclusions 
Adult stem cells serve to replenish and direct repair at sites of tissue injury throughout the body, 
and exhaustion of dysfunction of an adult stem cell population in vivo with age results in degenerative 
disease. Several finely tuned and contextually regulated pathways coordinate the activities of  
tissue-resident adult stem cell pools over time in response to a host of cellular stressors in an effort to 
maintain the balance between growth-promoting function and oncogenic resistance. Manipulation of 
one or more of these pathways has the potential to prevent or reverse the impact of advancing age on 
adult stem cell function, but is fraught with the difficulty of tipping the balance toward metabolic 
derangement, or more likely toward cancer formation. Harvest and manipulation of adult stem cells  
ex vivo for use in regenerative medicine is a piecemeal approach to addressing systemic age-related 
chronic illnesses, but for now may prove to be a safer approach. In this regard, it is noteworthy that the 
clinical safety of HSCs and MSCs has been well documented, not in the least on the basis of decades 
of successful clinical outcomes of heterologous bone marrow transplantation.  
Further development of therapeutic approaches to maintain these cells in vivo requires that the 
mechanistic basis of their age-related degeneration or renewal be understood. This is an area 
continually being informed by studies of early-onset aging syndromes and of families exhibiting 
extreme longevity. Transcriptional reprogramming, which effectively wipes away all signs of age from 
most cell types, is also yielding valuable insights into what makes a cell young or old. Rejuvenating 
stem cells to stave off aging safely will require highly innovative approaches, but the results of this 
research will have far-reaching implications for regenerative medicine.  
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